Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371266 · ClinicalTrials.gov registry record · NA
Glycemic Effects of Honey
A NA study, sponsored by USDA Grand Forks Human Nutrition Research Center.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT01371266: Completed NA study, sponsored by USDA Grand Forks Human Nutrition Research Center.
NCT01371266 is a NA study that has completed, run by USDA Grand Forks Human Nutrition Research Center. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01371266, a NA study, has completed, sponsored by USDA Grand Forks Human Nutrition Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
Honey has been used as a sweetener for centuries. Recent data indicate that honey consumption may have beneficial effects upon glucose intolerance, a health issue currently affecting 57 million Americans of every age and ethnicity. In order to evaluate the glycemic effect of honey, the investigators will carry out a human trial assessing biomarkers of blood glucose responses, insulin sensitivity, oxidative stress, and inflammatory markers. Our primary objective is to determine the glycemic effects of honey in comparison to sucrose and high fructose corn syrup (HFCS). The investigators hypothesize that honey will promote improved glucose tolerance and insulin sensitivity compared to both sucrose and high fructose corn syrup in normal glycemic and glucose intolerant adults.
Primary Outcome
Evaluation of the effect of the treatment nutritive sweeteners on glucose tolerance.
Interventions
- DIETARY_SUPPLEMENT Honey
- DIETARY_SUPPLEMENT High Fructose Corn Syrup 55 (HFCS 55)
- DIETARY_SUPPLEMENT CHO (sugar)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-08 |
| Phase | NA |
What the finished NCT01371266 record still lists
NCT01371266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Honey is the first listed.
NCT01371266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01371266 about?
NCT01371266 is a clinical study titled "Glycemic Effects of Honey". Honey has been used as a sweetener for centuries. Recent data indicate that honey consumption may have beneficial effects upon glucose intolerance, a health issue currently affecting 57 million Americans of every age and ethnicity. In order to evaluate the glycemic effect of honey, the investigators...
What is the current status of trial NCT01371266?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2011-06. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01371266?
The interventions under investigation include: Honey (DIETARY_SUPPLEMENT), High Fructose Corn Syrup 55 (HFCS 55) (DIETARY_SUPPLEMENT), CHO (sugar) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01371266?
This trial is sponsored by USDA Grand Forks Human Nutrition Research Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01371266's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia